Search Results
Search for other papers by Bruno Bouça in
Google Scholar
PubMed
Search for other papers by Ana Cláudia Martins in
Google Scholar
PubMed
Search for other papers by Paula Bogalho in
Google Scholar
PubMed
Search for other papers by Lídia Sousa in
Google Scholar
PubMed
Search for other papers by Tiago Bilhim in
Google Scholar
PubMed
Search for other papers by Filipe Veloso Gomes in
Google Scholar
PubMed
Search for other papers by Élia Coimbra in
Google Scholar
PubMed
Search for other papers by Ana Agapito in
Google Scholar
PubMed
Search for other papers by José Silva-Nunes in
Google Scholar
PubMed
dysfunction ( 5 ). Restoration of euthyroidism is of paramount importance in heart failure (HF) patients; it may be difficult to achieve with medication and it can also be refractory to a combination therapy of thionamides and glucocorticoids, making this a
Search for other papers by Georgios Kostopoulos in
Google Scholar
PubMed
Search for other papers by Grigoris Effraimidis in
Google Scholar
PubMed
,000 hospitalized hyperthyroid patients within ±30 days from the diagnosis of hyperthyroidism ( 11 ) and in 4.6% of 3966 hyperthyroid patients followed for a period of 5.5 years in comparison with the 2.9% of the 586,460 euthyroid subjects ( 12 ). Two recent studies
Search for other papers by Sébastien Verdickt in
Google Scholar
PubMed
Search for other papers by Falco Van Nes in
Google Scholar
PubMed
Search for other papers by Carolien Moyson in
Google Scholar
PubMed
Search for other papers by Toon Maes in
Google Scholar
PubMed
Search for other papers by Paul Van Crombrugge in
Google Scholar
PubMed
Search for other papers by Annick Van den Bruel in
Google Scholar
PubMed
Search for other papers by Brigitte Decallonne in
Google Scholar
PubMed
Introduction Radioactive iodine (RAI) has been used for the treatment of patients with Graves’ hyperthyroidism since the 1950s. After a single RAI administration, patients ideally become euthyroid but frequently develop hypothyroidism. On the
Search for other papers by Stefan Matei Constantinescu in
Google Scholar
PubMed
Search for other papers by Julien Hospel in
Google Scholar
PubMed
Search for other papers by Chantal Daumerie in
Google Scholar
PubMed
Search for other papers by Orsalia Alexopoulou in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
Search for other papers by Maria-Cristina Burlacu in
Google Scholar
PubMed
(85%) patients were treated with thiamazole, 3 with propylthiouracil, and 17 with both drugs. Median duration of medical treatment was 18.0 (12.0–41.3) months, and 65 out of 136 (48%) patients were treated for more than 18 months. Euthyroidism was
Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Birgitta Johansson in
Google Scholar
PubMed
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Search for other papers by Mats Holmberg in
Google Scholar
PubMed
Department of Pedagogical, Curricular and Professional Studies, Faculty of Education, University of Gothenburg, Gothenburg, Sweden
Search for other papers by Simon Skau in
Google Scholar
PubMed
Search for other papers by Helge Malmgren in
Google Scholar
PubMed
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
Introduction Untreated hyperthyroid patients with Graves’ disease (GD, autoimmune hyperthyroidism) often report fatigue, cognitive problems, and emotional distress. Once the patients are regarded as clinically recovered and euthyroid, the
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, UK
Search for other papers by Claire L Wood in
Google Scholar
PubMed
Search for other papers by Niamh Morrison in
Google Scholar
PubMed
Search for other papers by Michael Cole in
Google Scholar
PubMed
Search for other papers by Malcolm Donaldson in
Google Scholar
PubMed
Wellcome Trust-MRC Institute of Metabolic Sciences, University of Cambridge, Cambridge, UK
Search for other papers by David B Dunger in
Google Scholar
PubMed
Search for other papers by Ruth Wood in
Google Scholar
PubMed
Department of Endocrinology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
Search for other papers by Simon H S Pearce in
Google Scholar
PubMed
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, UK
Search for other papers by Timothy D Cheetham in
Google Scholar
PubMed
) with the aim of normalising thyroid hormone levels and then maintaining the patient in a euthyroid state. The ATD chosen in the UK is usually carbimazole (CBZ) because of the significant risk of liver dysfunction with propylthiouracil. ATD can be
Search for other papers by Marta Nascimento Soares in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal
Department of Surgery and Physiology, Cardiovascular Research Unit, Faculty of Medicine from the University of Porto, Porto, Portugal
Search for other papers by Marta Borges-Canha in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal
Institute for Research Innovation in Health, University of Porto, Porto, Portugal
Search for other papers by Celestino Neves in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal
Department of Surgery and Physiology, Cardiovascular Research Unit, Faculty of Medicine from the University of Porto, Porto, Portugal
Search for other papers by João Sérgio Neves in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal
Institute for Research Innovation in Health, University of Porto, Porto, Portugal
Search for other papers by Davide Carvalho in
Google Scholar
PubMed
previous studies compared the risk of thyroid cancer in patients with Graves' disease and in euthyroid individuals. Such approaches may be of interest to understand the increased risk of thyroid cancer in patients with Graves’ disease. However, from a
Institute of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Search for other papers by Mats Holmberg in
Google Scholar
PubMed
Search for other papers by Helge Malmgren in
Google Scholar
PubMed
Search for other papers by Peter F Berglund in
Google Scholar
PubMed
Search for other papers by Birgitta Johansson in
Google Scholar
PubMed
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Department of Endocrinology, Sahlgrenska University Hospital, Göteborg, Sweden
Gothenburg Centre for Person Centred-Care (GPCC), Göteborg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
in hyperthyroid GD patients has also been observed ( 18 , 23 ), but its recovery in euthyroidism was not associated with alleviated symptomatology ( 18 ). A few studies in GD subjects have found associations between depression, anxiety, and
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
The National Task Force in Hyperthyroidism, Swedish National System for Knowledge-Driven Management, Umeå, Sweden
Search for other papers by Agneta Lindo in
Google Scholar
PubMed
Department of Endocrinology and Diabetes, Örebro University Hospital, Örebro, Sweden
Search for other papers by Anne Breikert in
Google Scholar
PubMed
Thyroid Federation International, Kungsbacka, Sweden
Search for other papers by Peter Lakwijk in
Google Scholar
PubMed
Swedish Thyroid Association, Stockholm, Sweden
Search for other papers by Christin Lundberg in
Google Scholar
PubMed
Swedish Thyroid Association, Stockholm, Sweden
Search for other papers by Katarina Lunner in
Google Scholar
PubMed
Search for other papers by Birgitta Johansson in
Google Scholar
PubMed
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
The National Task Force in Hyperthyroidism, Swedish National System for Knowledge-Driven Management, Umeå, Sweden
Sweden and Wallenberg Center for Molecular and Translational Medicine, Västra Götaland Region, Göteborg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
these questionnaires are used today in research, having good reliability and validity ( 47 , 49 ). While euthyroidism is usually achieved rapidly under treatment, recovery of well-being is delayed for months in many patients and a negative impact on
Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
Search for other papers by Sara De Vincentis in
Google Scholar
PubMed
Search for other papers by Simona Loiacono in
Google Scholar
PubMed
Search for other papers by Eleonora Zanni in
Google Scholar
PubMed
Search for other papers by Roberta Sueri in
Google Scholar
PubMed
Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
Search for other papers by Maria Laura Monzani in
Google Scholar
PubMed
Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
Search for other papers by Daniele Santi in
Google Scholar
PubMed
Department of Endocrinology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Search for other papers by Ilaria Muller in
Google Scholar
PubMed
Search for other papers by Francesco Di Marco in
Google Scholar
PubMed
Search for other papers by Erica Crivicich in
Google Scholar
PubMed
Search for other papers by Mirco Armenti in
Google Scholar
PubMed
Department of Endocrinology and Diabetes Care and Prevention Unit, IRCCS Sant’Orsola-Malpighi Polyclinic, Bologna, Italy
Search for other papers by Uberto Pagotto in
Google Scholar
PubMed
Department of Endocrinology and Diabetes Care and Prevention Unit, IRCCS Sant’Orsola-Malpighi Polyclinic, Bologna, Italy
Search for other papers by Lorenzo Tucci in
Google Scholar
PubMed
Department of Endocrinology and Diabetes Care and Prevention Unit, IRCCS Sant’Orsola-Malpighi Polyclinic, Bologna, Italy
Search for other papers by Carolina Cecchetti in
Google Scholar
PubMed
Search for other papers by Tommaso Trenti in
Google Scholar
PubMed
Search for other papers by Valentina Pecoraro in
Google Scholar
PubMed
Search for other papers by Giulia Canu in
Google Scholar
PubMed
Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
Search for other papers by Manuela Simoni in
Google Scholar
PubMed
Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
Search for other papers by Giulia Brigante in
Google Scholar
PubMed
function (100% in COVID+ and 81% in COVID−) or developed permanent hypothyroidism requiring L-T4 therapy (0% in COVID+ and 8.3% in COVID−) ( Table 3 ). The percentages of dysthyroidism and euthyroidism at each visit are graphed in Fig. 3 . Figure 2